Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis: A Comprehensive Review

Ulcerative colitis is a chronic, relapsing-remitting inflammatory disorder of the colon, characterized by mucosal inflammation leading to symptoms of rectal bleeding, diarrhea, urgency, and abdominal pain. Moderate to severe cases often require escalation to advanced immune modulating therapies after failure or intolerance of conventional agents such as corticosteroids, aminosalicylates, and thiopurines. Biologics targeting tumor necrosis factor (TNF) revolutionized management, but primary non-response and loss of response remain challenges.

Vedolizumab is the first gut-selective, monoclonal antibody approved for patients with moderate to severe UC who have failed or are intolerant to prior therapies, including anti-TNF agents. By blocking the α4β7 integrin, vedolizumab impedes lymphocyte trafficking to gut tissue, reducing inflammation in a targeted manner.

·        Vedolizumab is a humanized IgG1 monoclonal antibody that specifically binds α4β7 integrin, inhibiting its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expressed on gut endothelium.

·        This selective blockade prevents pathogenic lymphocyte migration from the bloodstream into the gastrointestinal mucosa, attenuating the inflammatory response associated with UC while sparing other organs^[1][2].

Clinical Efficacy

Key Outcomes Demonstrated in Clinical Trials

Major Phase III Findings

·        Induction of remission at week 6: 16–17% vedolizumab vs. 5% placebo.

·        Maintenance of remission at week 52: up to 42.6% vedolizumab vs. 14.3% placebo with the subcutaneous formulation^[7].

·        Mucosal healing at week 52: 42–53% of vedolizumab-treated patients in several studies.

Graph: Clinical Remission Rates (Induction & Maintenance)

Real-World Effectiveness and Long-Term Data

Real-world cohort studies and long-term extension trials confirm that most patients achieving response at induction retain remission with ongoing vedolizumab. Remission rates remain stable past 1 year, with a significant proportion (52–88%) maintaining steroid-free remission and improved health-related quality of life through 2–3 years^[5][4][6].

Table: Long-Term Outcomes (GEMINI LTS Study)

Safety and Tolerability

Vedolizumab demonstrates an excellent safety profile compared to systemic biologics:

·        Most common adverse events: nasopharyngitis, headache, mild gastrointestinal infection^[3][2].

·        No increased incidence of serious infections or malignancies versus placebo.

·        No reported cases of progressive multifocal leukoencephalopathy (PML), a fatal neurologic complication seen with non-selective integrin inhibitors.

·        Injection site reactions for subcutaneous formulation are generally mild.

Table: Selected Adverse Events

Special Populations and Comparative Efficacy

·        Efficacy is consistent in anti-TNF naïve and anti-TNF-experienced patients, though slightly higher in TNF-naïve.

·        Subcutaneous vedolizumab is non-inferior to intravenous for maintaining remission, offering increased patient convenience^[7].

·        Comparative analyses and meta-analyses place vedolizumab as similar overall to TNF inhibitors and the JAK inhibitor tofacitinib for induction and maintenance efficacy, with a more favorable infection risk profile^[1].

Practical Considerations

Dosing Strategies

·        Induction dose: 300mg IV at weeks 0, 2, and 6.

·        Maintenance: 300mg IV every 8 weeks OR 108mg SC every 2 weeks (following at least 2 IV doses)^[8].

·        Increase dosing frequency to every 4 weeks for patients with loss of response may be considered^[5][4].

Monitoring

·        Regular assessment of clinical symptoms (e.g., Mayo score), endoscopic evaluation for mucosal healing.

·        Laboratory monitoring includes routine CBC, liver/renal function, and screening for tuberculosis prior to therapy.

Patient-Reported Outcomes and Quality of Life

Studies show vedolizumab treatment is associated with significant improvements in patient-reported symptom scores, reduction in school/work absences, and overall quality of life as measured by validated indices^[1][6][5].

Limitations and Future Directions

·        Long-term data on colectomy prevention is limited.

·        Uncertainties remain regarding optimal sequencing with other biologic or small molecule therapies.

·        Pediatric studies are ongoing, but early data are promising^[9].

·        Cost-effectiveness analysis is evolving; dedicated head-to-head trials are pending^[1][10].

Figures

1. Mechanism of Vedolizumab

Illustration: Vedolizumab blocks α4β7 integrin, inhibiting leukocyte trafficking to the inflamed colon.

2. Clinical Remission Over Time

Vedolizumab delivers effective, targeted, and well-tolerated treatment for moderate to severe ulcerative colitis, providing strong rates of clinical response, remission, and mucosal healing. Its safety advantages, gut selectivity, and both IV and SC administration options should inform individualized, evidence-based care for UC patients. Ongoing research will further define its optimal use among current and future therapeutic options.

1.      Bhandari, P., et al. "Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review." PubMed, 2021.

2.      Takatsu, N. "Vedolizumab in the Treatment of Ulcerative Colitis." PMC, 2020.

3.      Cochrane IBD Group. "Vedolizumab for the Treatment of Active and Inactive Ulcerative Colitis." Cochrane Database of Systematic Reviews, 2025.

4.      Loftus, E.V. Jr., et al. "Long-term Efficacy of Vedolizumab for Ulcerative Colitis." 2017.

5.      Christensen, B., et al. "Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety." Inflamm Bowel Dis, 2018.

6.      Sandborn, W.J., et al. "Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the VISIBLE trial." 2019.

7.      Entyvio (vedolizumab) Prescribing Information, Takeda, 2025.